Results 11 to 20 of about 704 (128)

Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures [PDF]

Journal of Antimicrobial Chemotherapy
Abstract Background New and shorter regimens against multi-drug resistant tuberculosis (TB) remain urgently needed. To inform treatment duration in clinical trials, this study aimed to identify human pharmacokinetic equivalent doses, antimycobacterial and sterilizing activity of a novel regimen ...
Kerstin Walter, Elin M Svensson, Norbert Heinrich   +2 more
exaly   +9 more sources

Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. [PDF]

PLoS ONE, 2012
There presently is no rapid method to assess the bactericidal activity of new regimens for tuberculosis. This study examined PNU-100480, TMC207, PA-824, SQ109, and pyrazinamide, singly and in various combinations, against intracellular M.
Robert S Wallis, Wesley Jakubiec, Mark Mitton-Fry, Lynn Ladutko, Sheldon Campbell, Darcy Paige, Annette Silvia, Paul F Miller   +7 more
doaj   +5 more sources

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial [PDF]

Lancet Infectious Diseases, The
Norbert Heinrich, Simon E Koele, Derek J Sloan   +2 more
exaly   +3 more sources

Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China [PDF]

Frontiers in Medicine, 2022
ObjectiveTo investigate the in vitro activities of five oxazolidinones in parallel against the reference strains of different mycobacterial species and clinical isolates of Mycobacterium tuberculosis (Mtb), and shed light on the differences in the ...
Chenqian Wang, Chenqian Wang, Guirong Wang, Fengmin Huo, Yi Xue, Junnan Jia, Lingling Dong, Liping Zhao, Fen Wang, Hairong Huang, Hongfei Duan   +10 more
doaj   +2 more sources

Assessment of Lipophilicity Parameters of Antimicrobial and Immunosuppressive Compounds [PDF]

Molecules, 2023
Lipophilicity in addition to the solubility, acid-base character and stability is one of the most important physicochemical parameters of a compound required to assess the ADMET properties (absorption, distribution, metabolism, excretion and toxicity) of
Dawid Wardecki, Małgorzata Dołowy, Katarzyna Bober-Majnusz   +2 more
doaj   +2 more sources

panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbe [PDF]

Trials
Background Newer oxazolidinones will be required to advance regimens in pan-TB indications. The addition of host-directed agents may help promote the recovery of lung function during TB treatment and prevent post-TB lung disease.
D. Mudzengi, S. Mashatole, Q. Xiang, C. Adrion, N. Glover, T. Ngwanto, J. Mdluli, S. Boniface, M. Rassool, B. Matome, L. Paramo, E. Svensson, A. Fasanmi, S. Angelo, M. Moyo, C. Marx, C. Khosa, L. Mokaba, N. Mofokeng, J. Lalashowi, C. Nacy, S. Charalambous, E. Fumane, V. Maphossa, T. Beattie, W. Brumskine, C. Venter, D. Mapamba, N. Heinrich, S. Rajaram, S. Kooverjee, L. Botha, M. Nell, A. Easton, S. Foraida, Robin Mark Warren, Issa Sabi, N. Ntinginya, R. S. Wallis, panTB-HM Consortium   +39 more
doaj   +2 more sources

Current Status and Perspectives of Antibacterial Agents Belonging to 2-Oxazolidinones [PDF]

Pharmaceuticals
In the last three decades, 2-oxazolidinones have emerged as an important class of inhibitors of bacterial protein synthesis, effective in the treatment of multidrug-resistant (MDR) bacterial infections. From a public health perspective, the importance of
Jessica Ceramella, Annaluisa Mariconda, Domenico Iacopetta, Maria Marra, Alessia Catalano, Paola Checconi, Stefano Aquaro, Carmela Saturnino, Pasquale Longo, Maria Stefania Sinicropi   +9 more
doaj   +2 more sources

Genomic-based genotype and drug susceptibility profile of Mycobacterium kansasii in China [PDF]

Frontiers in Microbiology
To analyze subtypes, microbiological characteristics and antimicrobial susceptibility of Mycobacterium kansasii in China, a total of 153 M. kansasii isolates, collected from national drug resistance surveillance, were genotyped with whole genome ...
Yiting Wang, Yiting Wang, Xichao Ou, Bing Zhao, Hui Xia, Yang Zheng, Yang Zhou, Ruida Xing, Yuanyuan Song, Shengfen Wang, Yanlin Zhao, Huiwen Zheng   +11 more
doaj   +2 more sources

ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis [PDF]

Trials
Background The standard of care (SOC) treatment for drug-susceptible pulmonary tuberculosis (DS-TB) consists of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE).
Linda J. Harrison, Gustavo E. Velásquez, Russell R. Kempker, Marjorie Z. Imperial, Eric Nuermberger, Susan E. Dorman, Elisa Ignatius, Janeway Granche, Patrick P. J. Phillips, Jennifer Furin, Eunsol Yang, Colleen Foley, Shawn Chiambah, Rochelle Rogers, Austin Van Grack, Jhoanna Roa, Justin Shenje, Sandy Nerette, Cecilia Kanyama, Rachel Bakyayita Kyeyune, Alberto Mendoza-Ticona, William Murtaugh, Salah Foraida, Melanie Goth, Andrew Vernon, Kelly E. Dooley, Radojka M. Savic   +26 more
doaj   +2 more sources

In Vitro efficacy comparison of linezolid, tedizolid, sutezolid and delpazolid against rapid growing Mycobacteria isolated in Beijing, China [PDF]

, 2020
Abstract The natural resistance of rapid growth Mycobacterium (RGM) against multiple antibiotics renders the treatment of caused infections less successful and time consuming. Therefore, new effective agents are urgently needed. The aim of this study was to evaluate the in vitro susceptibility of 115 isolates, constituting different RGM species,
Shu’an Wen, Xiaopan Gao, Weijie Zhao, Fengmin Huo, Guanglu Jiang, Lingling Dong, Liping Zhao, Fen Wang, Xia Yu, Hairong Huang   +9 more
openalex   +3 more sources